Merck Neuroscience Acquisition Brings a Startup With Parkinson’s, ALS Programs
Merck’s acquisition of Caraway Therapeutics adds programs for genetically defined neurodegenerative diseases. One of those programs addresses a target that was the focus of a different startup purchased by Merck in 2019.